United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 47.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 87,370 shares of the biotechnology company’s stock after acquiring an additional 28,192 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.20% of United Therapeutics worth $27,832,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. SG Americas Securities LLC increased its holdings in shares of United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of United Therapeutics by 19.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the period. Comerica Bank boosted its holdings in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after acquiring an additional 1,692 shares during the period. Finally, Campbell & CO Investment Adviser LLC raised its holdings in United Therapeutics by 163.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock worth $1,813,000 after purchasing an additional 5,120 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. UBS Group raised their target price on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Oppenheimer upped their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $350.36.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO James Edgemond sold 7,785 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The disclosure for this sale can be found here. Insiders sold a total of 110,922 shares of company stock worth $36,541,398 over the last ninety days. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

UTHR stock opened at $353.00 on Friday. The stock’s 50 day moving average price is $338.55 and its 200 day moving average price is $290.39. The firm has a market cap of $15.70 billion, a P/E ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the company earned $5.24 earnings per share. The firm’s revenue was up 19.8% compared to the same quarter last year. On average, sell-side analysts expect that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.